… Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new therapeutic
agents for … We selected phase 3 randomized clinical trials (RCTs) comparing HIF-PHIs and …

… all clinical trials (confined to phase II or III) about HIF-PHIs on anemia treatment. Hence, we
first conducted a meta-analysis of randomized controlled trials (… randomized controlled trials …

… yet to be proved in long-term clinical trials. One significant concern … clinical trials in the
United States; this report provides a focused review of HIF-PH inhibitors and their potential clinical …

… randomized controlled studies have demonstrated that the use of ESAs with a target
hemoglobin level of >13 g/dl has been associated with an increased rate of cardiovascular events …

… We conducted a meta-analysis of randomized clinical trials to assess the efficacy and safety
of HIF-PHI in non-dialysis-dependent CKD patients. Primary outcome was hemoglobin (Hb) …

… showed that hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) … among clinical
trials. We performed a systematic review and meta-analysis of randomized controlled trials …

… Randomized controlled trials comparing treatment with HIF-PHD inhibitors versus placebo …
and international clinical trial registries. Meta-analysis was performed on main outcomes with …

… For the final data set and for all analyses (including hemoglobin), blood was sent to Quest
Diagnostic Clinical Trials for analysis. Other laboratory tests were also analyzed centrally by …

… We performed a prospective, randomized, controlled study to … types of HIF-PH inhibitors.
The primary endpoint was a … the first head-to-head comparative study of HIF-PH inhibitors. …

… Background: Hypoxia-inducible factor prolyl hydroxylase inhibitors (… randomized controlled
trials (RCTs). Information about efficacy and safety was extracted and combined using random…